08
086820.KQ Biosolution Co.Ltd
- Market cap
- KRW 139B
- P/E
- 162.1x
- P/B
- 3.35x
- ROE
- -13.4%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 086820.KQ undervalued?
Graham numberThe Graham number of Biosolution Co.Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biosolution Co.Ltd fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-13.4%), below 10%.
ROA 0/1
Return on assets (-8.4%) is below the industry median (3.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (102.1%) is above the industry median (6.6%).
Revenue Growth 2/2
Revenue grew 14.6% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 10.9 years of the current cash burn.
PE vs Market 0/1
PE (162.1x) is above the market median (11.3x).
PE vs Industry 0/1
PE (162.1x) is above the industry median (19.4x).
PBV 0/1
Price to book (3.4x) is above the industry median (0.8x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 543.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Biosolution Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-…
Full company profileBiosolution Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biosolution Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.20B | 5.01B | 10.5B | 8.88B | 7.74B | 11.8B | 10.1B | 12.5B | 12.9B | 15.2B | 16.9B |
| Gross Profit | 1.30B | 2.54B | 7.01B | 5.90B | 4.30B | 7.61B | 5.93B | 8.06B | 8.16B | 9.59B | 11.4B |
| Operating Income | -3.13B | -1.81B | 1.08B | -1.87B | -3.33B | -1.57B | -5.29B | -5.14B | -10.1B | -4.34B | -3.56B |
| EBITDA | - | - | - | - | - | - | -2.92B | 4.56B | -6.89B | 5.26B | -930M |
| Net Income | -3.09B | -1.81B | 1.35B | -698M | -1.80B | -1.68B | -8.09B | -1.36B | -11.9B | 273M | -5.55B |
| EPS | -506 | -296 | 174 | -88 | -226 | -211 | -336 | -56 | -496 | 11 | -215 |
| Balance Sheet | |||||||||||
| Total Assets | 8.82B | 7.38B | 52.9B | 51.8B | 49.8B | 94.4B | 91.7B | 92.3B | 67.5B | 68.5B | 66.3B |
| Total Liabilities | 2.70B | 2.96B | 3.80B | 3.71B | 3.13B | 49.4B | 48.0B | 50.2B | 36.2B | 36.5B | 25.0B |
| Shareholders' Equity | 6.12B | 4.42B | 49.1B | 48.1B | 46.7B | 45.0B | 43.8B | 42.1B | 31.3B | 32.0B | 41.3B |
| Cash & Short-term Investments | 2.58B | 2.27B | 44.9B | 40.5B | 36.2B | 83.1B | 72.8B | 37.7B | 14.3B | 11.9B | 9.28B |
| Total Debt | - | - | - | 150M | 653M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.07B | -78.5M | 1.03B | -2.61B | -1.69B | 83.3M | -3.81B | 2.16B | -2.29B | -1.31B | -619M |
| Capital Expenditure | 1.14B | 188M | 707M | 2.18B | 1.39B | 663M | 4.08B | 1.16B | 1.23B | 732M | 233M |
| Free Cash Flow | - | - | - | - | -4.19B | -580M | -7.90B | 1.00B | -3.51B | -2.04B | -852M |
| Ratios | |||||||||||
| ROE | -50.4% | -40.9% | 2.7% | -1.5% | -3.9% | -3.7% | -18.5% | -3.2% | -38.2% | 0.9% | -13.4% |
| ROA | -35.0% | -24.5% | 2.5% | -1.3% | -3.6% | -1.8% | -8.8% | -1.5% | -17.7% | 0.4% | -8.4% |
| Net Profit Margin | -96.4% | -36.0% | 12.8% | -7.9% | -23.2% | -14.3% | -80.1% | -10.9% | -92.6% | 1.8% | -32.8% |
| Debt to Equity | - | - | - | 0.00x | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biosolution Co.Ltd dividends
Biosolution Co.Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 3:1 on May 27, 2025.
Who owns Biosolution Co.Ltd
- Insiders 17.66%
- Institutions 0.16%
- Public & others 82.18%
- Shares outstanding 25.8M
- Free float 21.2M
Biosolution Co.Ltd company profile
- Company name
- Biosolution Co.Ltd
- Ticker
- 086820.KQ
- ISIN
- KR7086820008
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 97
- Fiscal year end
- December
- Address
- Seoul Techno Park, Seoul, South Korea
- Phone
- 82 2 3446 8884
- Website
- biosolutions.co.kr
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds. It also provides reconstructed human micro-tissue models comprising KeraSkin, an epidermis model; KeraSkin-FT, a full-thickness skin model; KeraSkin-M, a pigmented skin model; corneal models; SoluAirway, a airway mucosa model; SoluOral, an oral mucosa model; SoluDPNeuron, a dopaminergic neuron model; SoluDANeuron, an islet model; and SoluLiver, a liver model. In addition, the company provides human-derived primary cell cultures and primary cells for in vitro research; bio advanced materials; and cosmetics raw materials. The company was formerly known as MCTT Bio Co., Ltd. and changed its name to Bio Solution Co.,Ltd. in January 2016. Bio Solution Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.